Trials / Not Yet Recruiting
Not Yet RecruitingNCT06524518
A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
Xuanwu Hospital Capital Medical University
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 213 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment. Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chemotherapy combined with immunization | MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2026-07-01
- Completion
- 2029-12-01
- First posted
- 2024-07-29
- Last updated
- 2024-08-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06524518. Inclusion in this directory is not an endorsement.